IFEREX 150- polysaccharide-iron complex capsule Nnodum Pharmaceuticals

iFEREX 150

Statement of identity

iFEREX 150 is an easily assimilated source of iron for treatment of uncomplicated iron deficiency anemia.

Healthn Claims

iFerex 150 is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.

Warning

Accidental overdose of iron-containing products is a leading cause in fatal poisoning of children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Dosage and Administration

Adults: One or two capsules daily or as directed by a physician.

Precautions

General: The type of anemia and underlying cause or causes should be determined before starting therapy with iFerex 150. Since the

anemia may be a result of systemic disturbance, such as recurrent blood loss, the underlying cause or causes should be corrected, if possible.

Safe Handling Warning

KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.

DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER WITH A RESISTANT CLOSURE.

STORAGE: Store at 20oC-25°C (68°- 77°F); excursions to 15°C-30°C (59°-86°F)

Principal Display Panel - IFEREX 150 ZIKs 63044-0203-01 iFEREX 150

Polysaccharide Iron

Complex Hematinic

100 Capsules

EACH CAPSULE CONTAINS:

Iron (elemental).....150 mg

(polysaccharide iron complex 326.1 mg)

INACTIVE INGREDIENTS: Black Iron oxide,FD&C Red #28, FD&C Yellow # 10, FD&C blue #1, FD&C red #40, FD&C yellow #6,gelatin, magnesium stearate, microcrystalline cellulose,Red Iron Oxide, and Titanium Dioxide

DESCRIPTION: iFerex 150 is a brown and orange capsule with marking "ziks 0203".

It is a product of ferric iron complexed to a low molecular weight polysaccharide.

INDICATIONS AND USAGE: iFerex 150 is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.

CONTRAINDICATIONS: iFerex 150 is indicated in patients with a known hypersensitivity

to any of the components of this product. Hemochromatosis and hemosiderosis are contraindications to iron therapy.

ADVERSE REACTIONS: Adverse reactions with iron therapy may include constipation, diarrhea, nausea, vomiting, dark stools, and abdomibal pain. Adverse reactions with iron tharapy are usually transient.

WARNING: Accidental overdose of iron-containing products is a leading cause in fatal poisoning of children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS: General: The type of anemia and underlying cause or causes should be determined before starting therapy with iFerex 150. Since the anemia may be a result of systemic disturbance, such as recurrent blood loss, the underlying cause or causes should be corrected, if possible.

DOSAGE AND ADMINISTRATION: Adults: One or two capsules daily or as directed by a physician.

KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.

DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER WITH A RESISTANT CLOSURE.


STORAGE: Store at 20°C-25°C (68°- 77°F); excursions to 15°C-30°C (59°-86°F)

HOW SUPPLIED: iFerex 150 capsules are supplied in 100 capsule per bottle.

Distributed by Nnodum Pharmaceuticals, Cincinnati, OH 45229

NP 6/18/09

3 63044 20301 2





reg

IFEREX 150

Product Information			
Product Type	DIETARY SUPPLEMENT	Item Code (Source)	NHRIC:63044-203
Route of Administration	ORAL		

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
IRON (UNII: E1UOL152H7) (IRON - UNII:E1UOL152H7)	IRON	150 mg	

Inactive Ingredients			
Ingredient Name	Strength		
FERROSOFERRIC OXIDE (UNII: XM0M87F357)			
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)			
FD&C RED NO. 40 (UNII: WZB9127XOA)			
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)			
GELATIN (UNII: 2G86QN327L)			
MAGNESIUM STEARATE (UNII: 70097M6I30)			
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)			
FERRIC OXIDE RED (UNII: 1K09F3G675)			
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)			

P	ackaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NHRIC:63044-203-61	10 in 1 BOX, UNIT-DOSE		
1		10 in 1 BLISTER PACK		
2	NHRIC:63044-203-01	100 in 1 BOTTLE		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
dietary supplement		03/01/2018	

Supplement Facts			
Serving Size :	Serving per Container :		
Amount Per Serving	% Daily Value		
color			
color			
imprint			
shape			

size (solid drugs)	7 mm	
scoring	1	

Labeler - Nnodum Pharmaceuticals (960457273)

Establishment			
Name	Address	ID/FEI	Business Operations
Contract Pharmacal Corporation		057795122	manufacture

Revised: 12/2023 Nnodum Pharmaceuticals